• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Pharma
    • Vaccines
    • Asia
    • Cell & Gene Therapy
    • Drug Delivery
    • Executives
  • Manufacturing
    • Facilities
    • Recalls
    • Warning Letters
  • Marketing
  • Special Reports
  • Fierce 50
    • Special Report
    • Awards Gala
  • Trending
    • Oncology
  • Awards
    • CRO Awards
    • Innovation Awards
    • Pharma Marketing Awards
  • Resources
    • Podcasts
    • Fierce Events
    • Industry Events
    • Webinars
    • Whitepapers
    • Survey
  • Events
  • Subscribe
Home
Subscribe
Hamburger Menu Hamburger Menu
  • Pharma
    • Vaccines
    • Asia
    • Cell & Gene Therapy
    • Drug Delivery
    • Executives
  • Manufacturing
    • Facilities
    • Recalls
    • Warning Letters
  • Marketing
  • Special Reports
  • Fierce 50
    • Special Report
    • Awards Gala
  • Trending
    • Oncology
  • Awards
    • CRO Awards
    • Innovation Awards
    • Pharma Marketing Awards
  • Resources
    • Podcasts
    • Fierce Events
    • Industry Events
    • Webinars
    • Whitepapers
    • Survey
  • Events
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us

Xeljanz

drug prices biologics drug costs IRA money cash payment co-pay
Pharma

ICER calls out drugmakers over 'unsupported' price hikes

In a new report, cost watchdog ICER called out Gilead, Johnson & Johnson, Novartis, Exelixis and Pfizer for implementing "unsupported" price hikes.
Fraiser Kansteiner Dec 12, 2024 2:24pm
European Medicines Agency

EMA cracks down on JAK drugs with new limitations

Oct 28, 2022 10:20am
IBD

Biora, with spin on Xeljanz nearing clinic, posts delivery data

Jul 11, 2022 12:45pm
Bristol Myers Squibb

Docs turning to Bristol's aging Orencia amid JAK safety woes

Apr 13, 2022 9:30am
AbbVie

FDA approves AbbVie's Rinvoq for ulcerative colitis

Mar 17, 2022 11:36am
FDA Building 2

EMA probes all JAKs after Xeljanz's safety concerns intensify

Feb 11, 2022 3:51pm

Home
  • Connect
    • The Team
    • Advertise
    • Marketing Kit
    • Let's Talk
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Biotech
    • Fierce Healthcare
    • Fierce Pharma
  • Our Events
    • Life Sciences Events
©2025 Questex LLC All rights reserved.
Terms of use
Privacy Policy
Privacy Settings